Published in:
Open Access
01-12-2020 | Coronary Heart Disease | Research
Prognostic value of NT-proBNP in patients with severe COVID-19
Authors:
Lei Gao, Dan Jiang, Xue-song Wen, Xiao-cheng Cheng, Min Sun, Bin He, Lin-na You, Peng Lei, Xiao-wei Tan, Shu Qin, Guo-qiang Cai, Dong-ying Zhang
Published in:
Respiratory Research
|
Issue 1/2020
Login to get access
Abstract
Background
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China has been declared a public health emergency of international concern. The cardiac injury is a common condition among the hospitalized patients with COVID-19. However, whether N terminal pro B type natriuretic peptide (NT-proBNP) predicted outcome of severe COVID-19 patients was unknown.
Methods
The study initially enrolled 102 patients with severe COVID-19 from a continuous sample. After screening out the ineligible cases, 54 patients were analyzed in this study. The primary outcome was in-hospital death defined as the case fatality rate. Research information and following-up data were obtained from their medical records.
Results
The best cut-off value of NT-proBNP for predicting in-hospital death was 88.64 pg/mL with the sensitivity for 100% and the specificity for 66.67%. Patients with high NT-proBNP values (> 88.64 pg/mL) had a significantly increased risk of death during the days of following-up compared with those with low values (≤88.64 pg/mL). After adjustment for potential risk factors, NT-proBNP was independently correlated with in-hospital death.
Conclusion
NT-proBNP might be an independent risk factor for in-hospital death in patients with severe COVID-19.